Radiation Aimed at Spread Sites in Young Patients With Sarcoma
Tests targeted radiation at metastatic sites in children and young adults with sarcoma.
Plain-language title generated from the registry record
Registry title: Targeted Oligometastatic Radiation in Pediatric and Young Adult Patients With Soft Tissue and Bone Sarcoma
Key facts
- Where
- Baltimore, Minneapolis, and Washington D.C., United StatesSee the 3 sites
Where in United States
- Johns Hopkins HospitalBaltimore, United StatesTaking people
- University of MinnesotaMinneapolis, United StatesTaking people
- Sibley Memorial HospitalWashington D.C., United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Trial code
- NCT06796543
- Record updated
- 13 July 2026
- Original description
This study is designed for children, adolescents and young adults undergoing radiation therapy for metastatic sarcoma. The aim of the study is to investigate if the investigators can improve the overall survival of these patients by targeting metastatic sites with radiation.Read full original descriptionShow less
Targeted Oligometastatic Radiation in Pediatric and Young Adult Patients With Soft Tissue and Bone Sarcoma
This study is designed for children, adolescents and young adults undergoing radiation therapy for metastatic sarcoma. The aim of the study is to investigate if the investigators can improve the overall survival of these patients by targeting metastatic sites with radiation.
Stratum A Inclusion Criteria:; Patients must be aged < 39 years at time of enrollment; Patients must have a Karnofsky or Lansky performance score of 70 or greater or Eastern Cooperative Oncology Group (ECOG) performance status of 0-1; Patients must have newly diagnosed histologically or molecularly confirmed soft tissue or bone sarcoma at any site; Patients must have metastatic disease that is measurable and this is defined as at least one lesion discontinuous from the primary that can be accurately measured in at least one dimension (longest diameter to be recorded) as > 3mm with CT scan within 3 weeks from treatment start; Stratum B Inclusion Criteria:; Patients must have a Karnofsky or Lansky performance score of 70 or greater or ECOG performance status of 0-1; Patients must have radiographic, histologic or molecular confirmation of progressive soft tissue or bone sarcoma at any site that was initially diagnosed at age < 39 years. Progression includes progression at a new site or known sites of prior disease (e.g. recurrent); Patients must have metastatic disease that is measurable and this is defined as at least one lesion discontinuous from the primary that can be accurately measured in at least one dimension (longest diameter to be recorded) as > 3mm with CT scan; Radiation to at least one site is being recommended as part of second line therapy; Stratum A Exclusion Criteria:; Brain or intracranial metastases, including leptomeningeal disease; Clinical or radiologic evidence of spinal cord compression requiring emergent radiation treatment; Positive bone marrow biopsy for non-pelvic primary and greater than eight bone metastases. Presence of parenchymal lung metastases is considered as one metastasis, irrespective of how many lung nodules are present; Evidence of any non-measurable metastatic disease including but not limited to leptomeningeal disease, malignant ascites and malignant pleural or pericardial effusions; Pregnancy; Stratum B Exclusion Criteria:; Brain or intracranial metastases, including leptomeningeal disease; Clinical or radiologic evidence of spinal cord compression requiring emergent radiation treatment; Evidence of any non-measurable metastatic disease including but not limited to leptomeningeal disease, malignant ascites and malignant pleural or pericardial effusions; Pregnancy.